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Low-grade serous ovarian carcinoma represents a minority of ovar-
ian cancers, and is distinct from high-grade serous ovarian carcinoma
in its development, survival rates, and response to therapy. We present
a case of advancedwidelymetastatic low-grade serous ovarian carcino-
ma successfully treated with Cyberknife radiotherapy followed by
anastrozole at progression.
Case report
A 45 year-old morbidly obese (BMI 41) African–American woman
presented with a new sensation of chest discomfort. Her initial workup
was negative. A few months later, she presented with a new left-sided
mass on her back. The mass was excised and was identiﬁed as a low-
grade papillary serous carcinoma consistent with an ovarian origin
(Fig. 1A). On further investigation, a CT scan identiﬁed an irregularly-
shaped calciﬁed chestmass along the right cardiac border, multiple pul-
monary nodules, and a pelvic mass measuring 6 × 7 cm (Fig. 2). A PET/
CT demonstrated a large right mediastinal mass with irregular calciﬁca-⁎ Corresponding author at: Department of Obstetrics and Gynecology, University
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creased uptake was identiﬁed in multiple pulmonary nodules, bilateral
axillary and inguinal lymph nodes, and soft tissue nodules in the abdo-
men suspicious formalignancy. An echocardiogramdemonstrated com-
pression of the right atrium by the mediastinal mass.
A right-sided video-assisted thoracoscopic surgery (VATS) was per-
formed, and the mass was noted to involve the phrenic nerve and the
superior vena cava, rendering it unresectable. A right middle lobe
wedge resectionwas performed at the time of the VATS, and the pathol-
ogy results revealed a low-grade papillary serous carcinoma. A few
weeks later, the patient underwent a laparoscopic bilateral salpingo-
oophorectomy, omentectomy, and diaphragmatic biopsy. The pathology
of these specimens revealed bilateral serous borderline ovarian
tumors with microinvasion on the left (Fig. 1B), an omental implant in-
deﬁnite for invasion, and positive peritoneal cytology. Her initial CA-125
at the time of surgery was 215.9. Histologic stains revealed the tumor to
be estrogen and progesterone receptor positive, positive for CK7 and
vimentin, and negative for CEA, CK20, CD10, and TTF-1. PAX8 and WT-1
immunostaining of tumor samples conﬁrmed that themetastatic deposits
were derived from the primary ovarian tumor. The patientwas diagnosed
with FIGO stage IV low-grade papillary serous carcinoma of the ovary.
The compressive effects of the tumor on the pericardium resulted
in extreme exercise intolerance and shortness of breath at rest. The
unresectable mediastinal mass was treated with Cyberknife radiosur-
gery at a dose of 36Gy in two fractions over four days. Following treat-
ment of the cardiac lesion, the patient was started on tamoxifen
20 mg by mouth twice daily.
The patient's disease remained stable on tamoxifen for ﬁve months,
after which the metastatic nodule in her anterior abdominal wall
was found to be increasing in size on a routine surveillance CT scan.
Megestrol acetate 80 mg twice daily for one week was then added to
her regimen, followed by three weeks of tamoxifen. On this regimen the
patient's disease remained stable for 8 additional months. Routine imag-
ing demonstrated progression, with an increase in the size and number of
pulmonary nodules, an increase in the size of an abdominal wall metasta-
sis, and a rise in CA-125 from 33.1U/mL to 80.5U/mL. The patient also re-
ported anewbreastmasswhich, on core biopsy, demonstrated apapillary
lesion conﬁrmed to be low-grade papillary serous carcinoma consistent
with metastatic disease by immunohistochemical staining for PAX8 and
WT1 (Fig. 1C). Three months later, the patient underwent resection of
the metastatic mass in her anterior abdominal wall, which demonstrated
pathologic changes consistentwith low-grade papillary serous carcinoma
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Fig. 1. Serous borderline tumor withmicroinvasion andmetastatic low grade papillary serous carcinoma. (A) Initial biopsy of backmass shows a papillary epithelial tumorwith conﬂuent
glandular pattern and multiple calciﬁed psammoma bodies (H&E stain, 20X). Low nuclear grade and positivity for PAX8 andWT1 indicate a metastatic low grade papillary serous carci-
noma. (B) Subsequent excision of ovarian masses shows bilateral serous borderline tumor with microinvasion on the left side (H&E stain, 4X). Note the complex papillary growth with
surrounding clear spaces within the ﬁbrovascular core of one of the borderline tumor stalks. (C) Core needle biopsy of breast lesion (WT1 immunohistochemical stain, 20X).WT1 staining
is positive in tumor cells and negative in adjacent benign ductal epithelium excluding a primary papillary lesion of the breast and conﬁrming metastasis from pelvic low grade papillary
serous carcinoma. (D) Excision of abdominal lesion two years following primary diagnosis demonstrates increased nuclear grade within the metastatic tumor (H&E, 20X).
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tumor (Fig. 1D). The subjective impression of increased cytologic atypia
in this abdominal wall lesion was veriﬁed by quantiﬁcation of theFig. 2. CT image of right mediastinal mass compressing the right atrium.proliferative fraction by Ki-67 immunostaining (proliferative fraction =
18.0% compared with 3.6% in the original serous borderline tumor, 8.3%
in the localized area of microinvasive borderline tumor, and 9.3% in the
2008 metastatic focus of low grade papillary serous carcinoma in the
lung). Tamoxifen and megestrol acetate were discontinued, and she was
instead started on anastrozole 1 mg by mouth daily. She remains stable
on anastrozole. Serial CT scans every 6 months have demonstrated no
evidence of disease progression for 42 months.Discussion
Low-grade serous ovarian carcinoma comprises 10 percent of all
ovarian cancers (Schmeler and Gershenson, 2008). It is deﬁned by
mild to moderate nuclear atypia and up to 12 mitoses per high-power
ﬁeld. High-grade serous carcinoma, in comparison, is deﬁned bymarked
nuclear atypia and more than 12 mitoses per 10 high-power ﬁeld
(Schmeler and Gershenson, 2008).
Patients with low-grade serous carcinoma typically present at a
younger age than patients with high-grade serous carcinoma; 45–
57 years and 44–65 years, respectively (Vang et al., 2009). Although
both types present at advanced stages, the median survival for low-
grade serous carcinoma is 6.8 years, compared to 1.7 years for high-
grade serous carcinoma (Vang et al., 2009).
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low-grade endometrioid, mucinous, clear cell, and Brenner tumors)
and Type II (high-grade serous, high-grade endometrioid, carcinosarco-
ma, and undifferentiated tumors) (Lim and Oliva, 2013). Type I tumors
are characterized by genetic stability, and develop from benign, bor-
derline, or endometriosis precursors (Lim and Oliva, 2013). Serous bor-
derline tumors are occasionally linked to low-grade serous ovarian
carcinoma through the process of microinvasion, although this occurs
in a small minority of cases (Hogg et al., 2007).
Ovarian cancer, both low-grade and high-grade, often presents at ad-
vanced stages with disease outside of the pelvis. When a patient's pre-
senting complaint is unrelated to pelvic or abdominal symptoms, as
with this case, it is important to obtain an accurate diagnosis. PAX8 and
WT1 are two immunohistochemical markers that are used in the identi-
ﬁcation ofmetastatic ovarian carcinoma: PAX 8 has a detection rate of 87
percent for carcinomas of Mullerian origin, while WT1 has a detection
rate of 63 percent (Zhao et al., 2012). Combined testing for the two
increases detection rate to 94 percent (Zhao et al., 2012). The tumor sam-
ples obtained from this patient were all positive for PAX8 and WT1.
Low-grade serous ovarian carcinomas have a poor response to tradi-
tional chemotherapy. Standard chemotherapy for high-grade ovarian
cancer typically consists of platinum and taxane based combinations.
In a study of neoadjuvant traditional chemotherapy in low-grade serous
ovarian carcinoma, only 4 percent of patients responded with improve-
ment in disease status (Schmeler et al., 2008). Adjuvant chemotherapy
is associated with a similarly poor response rate (Schmeler and
Gershenson, 2008; Vang et al., 2009). This characteristic poor response
is attributed to the differences in molecular proﬁles and proliferative
activity between low and high-grade serous carcinomas (Vang et al.,
2009).
Estrogen (ER) andprogesterone (PR) receptors are variably expressed
in ovarian cancers and confer a survival advantage. In a large Danish
study of ER/PR expression in ovarian tumors from 773 patients, 36
percent of tumors were found to be ER positive, and 20 percent of tu-
mors were found to be PR positive (Høgdall et al., 2007). An analysis
of survival data demonstrated that ER and PR positivity of 10 percent
or higher was independently predictive of disease-speciﬁc survival
(Høgdall et al., 2007). ER and PR receptors are also expressed at signif-
icantly higher levels in low-grade serous ovarian carcinomas than in
high-grade (Schmeler and Gershenson, 2008).
Cyberknife stereotactic radiosurgery is image-guided robotically-
controlled external beam radiation that enables highly conformal admin-
istration of radiotherapy to target lesions within the body; in this case,
the chest. Both respiratory and cardiac motions are accounted for in
real time by synchronous imaging just prior to delivery of the prescribed
therapy (Kunos et al., 2012). This is the ﬁrst report in the literature of
Cyberknife stereotactic radiosurgery being used to treat low-grade se-
rous ovarian carcinoma. This patient had an excellent response with res-
olution of her symptoms and improvement of her performance status.
Tamoxifen, a selective estrogen receptormodulator, is awidely-used
agent for the treatment and prevention of breast cancer, particularly in
the setting of estrogen-receptor positivity. A retrospective review of its
use in the treatment of recurrent small volume ovarian, fallopian tube,
and peritoneal cancers demonstrated that it may have some success in
the management of recurrence of these gynecologic malignancies
(Markman et al., 2004). This therapy was effective in our patient for
ﬁve months, after which she developed progressive disease.
The idea of using pharmacologic therapies to treat hormone-
dependent disease processes has been used for many years. Aromatase
is an enzyme that is expressed in many tissues in the body, including
breast, gonads, endometrium, skin, and bone. Tissues that express aro-
matase are capable of converting systemic circulating androgens to es-
trogens. Anastrozole, a potent non-steroidal aromatase inhibitor, ﬁrst
became available in 1995. Anastrozole has been used for breast cancer
treatments and in gynecology for endometriosis treatment and ovula-
tion induction, and for the treatment of ovarian granulosa cell tumors(Nothnick, 2011). The Arimidex, Tamoxifen, Alone or in Combination
(ATAC) trial, a large multi-center trial on the use of anastrozole and ta-
moxifen in the adjuvant treatment of early-stage breast cancer, demon-
strated the advantage of anastrozole over tamoxifen: patients treated
with anastrozole had lower rates of local and distant recurrence,
and had longer disease-free survival (Cuzick et al., 2010). The authors
of the ATAC trial have hypothesized that the increased efﬁcacy of
anastrozole may be attributed to the profound estrogen deprivation as-
sociatedwith anastrozole compared to the antagonist-partial agonist ef-
fect of tamoxifen, which may explain why anastrazole worked for this
patient, while tamoxifen did not (Baum et al., 2002). There have been
no cases reported in the literature to date of the use of anastrozole in
the treatment of low-grade serous ovarian carcinoma.
Our patient presentedwith a symptomatic unresectable cardiac lesion
that was successfully treated with Cyberknife radiotherapy. Her pulmo-
nary nodules and other metastatic lesions were stable on tamoxifen for
ﬁve months, and then a combination of tamoxifen and megestrol acetate
for eight additional months. At progression, she underwent resection of a
symptomatic abdominal wall mass and began anastrozole therapy. She
continues to enjoy stable disease after forty-two months of therapy.
Conclusion
Low-grade papillary serous ovarian carcinoma is a malignancy with
unique features. It does not, in general, respond well to chemotherapy
and there is no standard therapy to treat cases of advanced disease. Sur-
gical resection was not feasible in this case. This case demonstrates the
excellent long-term control of advanced, unresectable low-grade papil-
lary serous ovarian carcinoma using Cyberknife radiotherapy and sup-
ports the use of anastrozole to prevent disease progression.
Written informed consent was obtained from the patient for publi-
cation of this case report and related images. A copy of this consent is
available for review by the Editor-in-Chief of this journal upon request.
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